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Abstract
Objective—Although higher rates of depression are found among individuals with type 2
diabetes, it remains unknown if the presence of depressive symptoms is associated with
heightened metabolic risk for the development of type 2 diabetes among youth. The objective of
this study was to evaluate whether depressive symptoms in obese adolescents are associated with
impaired β-cell function relative to insulin sensitivity (oral disposition index [oDI]) and/or
dysglycemia or prediabetes, predictors of type 2 diabetes development.
Research Design and Methods—Fasting and oral glucose tolerance test (OGTT)-derived
indices of glucose tolerance, insulin sensitivity, secretion and oDI were evaluated in obese youth
(n=56, age 15.0 ± 1.6 y, 68% female). The Children’s Depression Inventory (CDI) was utilized to
determine depressive symptomatology.
Results—Despite no association between depressive symptoms and measures of adiposity, youth
with higher depressive symptoms had 1) significantly higher fasting and stimulated glucose levels
(13% higher glucose area under the OGTT curve), 2) ~50% lower oDI, and 3) a 50% frequency of
prediabetes.
Conclusions—These data point to an important relationship between depressive symptoms and
a heightened metabolic risk for type 2 diabetes in obese adolescents, including prediabetes and
impairment in β-cell function relative to insulin sensitivity. While the directionality of these
relationships is unknown, it should be determined if treating one disorder improves the other or
vice versa.
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Introduction
Adolescents often suffer from depressive symptoms, which can be associated with a variety
of adverse effects on physical and metabolic health. The co-occurrence of depression and
chronic medical illness, including diabetes, has been shown in multiple studies in adults and
children; however, the directionality of this relationship is unclear (1–6). Moreover,
although previous studies have linked depressive symptoms with markers of decreased
insulin sensitivity (increased fasting insulin and Homeostasis Model Assessment (HOMA)
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levels) in non-diabetic youth (7–9), no pediatric studies have examined potential
associations between depressive symptoms and metabolic risk markers for type 2 diabetes.
In longitudinal studies of adults without diabetes, oral disposition index (oDI), a measure of
insulin secretion relative to insulin sensitivity, is shown to be the strongest metabolic
predictor of future diabetes (10, 11). In youth, oDI correlates strongly with clamp-derived
DI, declines across the spectrum of glucose intolerance, and predicts the development of
dysglycemia after 2 years (12, 13). Therefore, the primary objective of this study was to
evaluate the relationships between self-endorsed depressive symptoms and metabolic risk
markers for type 2 diabetes including dysglycemia and β-cell function relative to insulin
sensitivity, oDI, measured during oral glucose tolerance testing (OGTT) in obese non-
diabetic adolescents.
Methods
A total of 56 obese adolescents (age 15.0 ± 1.6 y, 68% female, 61% non-Hispanic white,
32% non-Hispanic black, 7% bi-racial), including 23 girls with untreated polycystic ovary
syndrome (PCOS), who were participants in our National Institutes of Health-funded studies
enrolling obese adolescents (R03HD057532, K23KD061598) who had completed baseline
OGTT and standardized questionnaires for depression screening. The questionnaires were
administered prior to giving the results of the OGTT testing to the participants. Participants
were patients referred to an obesity clinic as part of their medical care who were invited to
participate in these IRB-approved protocols. When a patient expressed interest, a research
assistant described the study procedures, assessed eligibility, and answered questions, and
obtained informed assent/consent prior to participation. Data from some of these participants
were reported previously (14–17). Eligibility criteria were: BMI ≥ 95th percentile, age 12–18
years, and Tanner stage III–V puberty. Exclusion criteria included chronic disease or
medications associated with glucose intolerance, diabetes, and syndromic obesity, such as
Prader-Willi syndrome or hypothalamic obesity.
Study Procedures
Study procedures were performed during a single visit to the Pediatric Clinical and
Translational Research Center. Glycosylated hemoglobin (HbA1C) and a standard 2-hour
OGTT (1.75 g/kg, maximum 75 g) were performed to evaluate glucose tolerance and
calculate insulin sensitivity and secretion indices and oDI. Blood samples were drawn at
−15, 0, 15,30, 60, 90, and 120 minutes for determination of glucose and insulin levels as
previously described (14, 18). Plasma glucose was measured by the glucose oxidase method.
Plasma insulin concentrations were determined by multiplexed immunoassay using
fluorescent microspheres(Millipore)and the Luminex-200 system (Luminex Corporation).
The Children’s Depression Inventory (CDI) was used to assess depressive symptoms and
results were reviewed immediately by a research team member who had access to
consultation with a licensed clinical psychologist if necessary (19). The CDI is a widely
used measure of depressive symptoms comprised of 27 items loading on five primary
factors: negative mood, interpersonal problems, ineffectiveness, anhedonia, and negative
self-esteem. The measure was originally normed on a sample of 1,266 public school students
ranging in age from 7–16 (47% male; 77% Caucasian and 23% African American, Native
American or Hispanic; largely middle class with wide socioeconomic range), and was also
assessed on a clinical sample of 134 adolescents with depressive disorders (47% male; 62%
Caucasian and 34.3% African American; 67.9% from lower socioeconomic status) (19). The
CDI is repeatedly shown to be a reliable and valid measure of depressive symptoms with
high test-retest reliability and the capacity to detect changes in depressive symptoms over
treatment (20, 21).
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Calculations
Fasting glucose and insulin were obtained from the baseline measurements of the OGTT.
The inverse of fasting insulin (1/fasting insulin) was utilized as a surrogate estimate of
insulin sensitivity (22). Early phase insulin secretion during the OGTT was expressed as the
insulinogenic index (IGI) or the ratio of the incremental response of insulin to glucose at 30
minutes of the OGTT (IGI30) (13). One subject had a 30 minute insulin level that was
essentially the same as the fasting insulin, producing a zero value (−0.09), which was
included in the statistical analysis. The oDI was calculated as IGI30 × 1/fasting insulin (13).
One subject with a low CDI score had a missing value for glucose at 30 minutes during the
OGTT and thus had missing data for IGI30 and oDI.
Statistical Analysis
Analyses were conducted using SPSS 19.0 and all tests were two-tailed. Goodness-of-fit
tests (Kolmogorov-Smirnov and Anderson Darling) and quantile-quantile (Q-Q) plots were
used to assess normality of distribution.
Individuals with lower versus higher total CDI scores (<13 vs≥13) were compared. The
utility of a categorical approach at this cut-point is accepted as useful for the purposes of
screening for the potential of a depressive disorder (23–25). This cut-point has also been
used in a previous pediatric study evaluating associations between depressive symptoms and
fasting insulin outcomes (8). The chi-square test for independence or the Fisher’s exact
probability test was used to compare categorical variables. Two-sided t tests were used to
compare normally distributed continuous variables and Mann Whitney U tests to compare
non-normally distributed continuous variables. Statistical power was determined to be >90%
to detect a 50% difference in oDI, the primary outcome, among the CDI groups, α = 0.05.
CDI scores as a continuous variable were not normally distributed, even after applying
standard transformation approaches, thus nonparametric Spearman rank-order correlation
coefficients were calculated to quantify the associations between CDI scores,
anthropometric measures, indices of glucose tolerance and oDI. This strategy was used in
addition to dichotomizing the CDI data because existing literature suggests that even sub-
threshold depressive symptomatology is associated with inferior insulin sensitivity in youth
(7, 9). CDI T-scores, rather than total scores, were utilized in correlation analyses because
the T-score already accounts for age and gender. Partial correlation coefficients controlling
for BMI were also calculated to evaluate associations between depressive symptoms and
glucose homeostasis parameters. Natural logarithm transformation was performed to
accommodate skewness of the observed data when plotting the relationship between the CDI
and the oDI. Statistical power was determined to be 80% to detect a linear association (r =
0.40, α = 0.05) between the CDI total score and the oDI. In addition, we evaluated whether
the CDI total scores were associated with a worse metabolic state (lower oDI, higher fasting,
2-hr, and AUC glucose values) while also accounting for gender, race, age, and BMI, by
performing standard multiple regressions using metabolic outcomes of interest as the
dependent variables and CDI score, gender, age, race, and BMI as the independent variables.
Results
The mean CDI score for the study population was 9 ± 8; the median score was 7; range 0–
30. Median CDI scores did not vary by race (7.0 in non-Hispanic whites, 7.5 in non-
Hispanic blacks, and 6.5 in biracial participants, p = 0.84) and the distribution of CDI scores
was the same for males and females (p = 0.53). Demographic, anthropometric, and
metabolic characteristics of the participants grouped by CDI score cut off of 13 are shown in
Table I. There were no significant differences in age (p = 0.66), sex (p = 0.75), BMI (p =
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0.95), or waist circumference (p = 0.83) (Table 1), nor were there significant linear
relationships between CDI score and these measures. There was a trend for those with
higher depressive symptoms to be of non-Hispanic white race (p = 0.06).
HbA1C and fasting insulin did not differ significantly among the groups (Table I, p = 0.24
for HbA1C and p = 0.16 for fasting insulin). However, fasting and 2-hr glucose levels were
significantly higher in the group with higher CDI scores (Table I). Fifty percent of the
participants with CDI scores ≥13 had evidence of pre-diabetes (impaired fasting glucose
[IFG] or impaired glucose tolerance [IGT]) as compared with 19% of the participants with
lower CDI scores (Table I, p = 0.04). The percentage of participants with PCOS did not
differ among the groups (Table I, p = 1.0).
The acute insulin response to glucose, IGI30, during the OGTT was ~41% lower (p = 0.02),
and the oDI was ~50% lower (p = 0.001) among those with greater depressive symptoms
(Table I). The group with higher CDI scores also had significantly higher glucose AUC, but
the insulin AUC was not different during the OGTT (p = 0.91), demonstrating relative
insulin deficiency in this group (Table I).
Associations between log-transformed CDI T-score and (A) fasting glucose, (B) OGTT 2-hr
glucose, (C) OGTT glucose AUC and (D) oral disposition index (oDI) are shown in Figure I
(subjects with CDI total score < 13 are represented by empty circles and CDI total score ≥
13 are represented by filled circles). There were significant associations between the CDI
and OGTT 2-hr glucose (r = 0.329, p = 0.013; adjusted for BMI r = 0.364, p = 0.007) and
oDI (r = −0.337, p = 0.013; adjusted for BMI r = −0.435, p = 0.003). Generally there were
no correlations between insulin sensitivity indices and CDI scores.
To clarify whether the associations with CDI were independent of the demographic and
anthropometric characteristics of the cohort, standard multiple regression analyses were
conducted with the metabolic variables (fasting glucose, OGTT 2-hr glucose, OGTT glucose
AUC and oDI) as the dependent variables and CDI, gender, age, race, and BMI as the
independent variables (Table II). CDI was a significant contributor to OGTT glucose AUC
and oDI. The model explained 21% of the variance in OGTT glucose AUC (R2 = 0.209, p =
0.041), and only CDI contributed significantly (β = 0.348, p = 0.011). The model explained
23% of the variance in oDI (R2 = 0.233, p = 0.02). Significant contributors to the oDI score
were the CDI score (β =−0.262, p = 0.047) and race (β = 0.273, p = 0.037; non-white race
was associated with higher oDI). Gender, age, and BMI did not contribute significantly to
the models.
There were 23 girls with untreated polycystic ovary syndrome who were included in the
analysis. As women with PCOS are known to have greater risk for impaired glucose
tolerance and type 2 diabetes, this may have impacted the measured relationships. When this
group was analyzed separately, the relationship between CDI and oDI was found to be very
significant among this group of girls (r = −0.521, p = 0.015). Associations between CDI
score and the other parameters of pre-diabetes (fasting, OGTT 2-hr and AUC glucose) were
not significant in this smaller sample.
Discussion
In this study we found that higher levels of depressive symptoms in obese youth were
associated with 1) lower insulin secretion relative to insulin sensitivity (oDI), indicative of
impaired β-cell function, 2) higher fasting and OGTT-stimulated glucose levels indicative of
lower glucose tolerance, and 3) higher frequency of prediabetes (either IFG or IGT). This is
despite no association between CDI score and BMI or waist circumference. In cross-
sectional and longitudinal cohort studies of youth without diabetes, insulin secretion
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adjusted for insulin sensitivity is a strong metabolic predictor of IGT and diabetes (12, 13,
26, 27). In multiple linear regression models, CDI scores contributed significantly to OGTT
glucose AUC and oDI values when accounting for effects of race, gender, age, and BMI. We
also found non-white race to be associated with higher oDI. This finding is in agreement
with our previously published data showing that the quantitative relationship between
insulin sensitivity and first-phase insulin differs by race, with non-diabetic black children
having greater first-phase insulin secretion, as compared with their white peers with similar
BMIs (28).
Our findings that youth who endorse more depressive symptoms have a higher frequency of
pre-diabetes would suggest a heightened risk for the future development of type 2 diabetes
in them. Findings from the Treatment Options for Type 2 Diabetes in Youth (TODAY)
study revealed rates of depression in adolescents with diabetes were comparable to the rates
of depression in obese non-diabetic adolescents (29). The TODAY study cohort was
comprised of patients recruited after the diagnosis and start of treatment of diabetes, and
more than 80% of the participants were of minority race/ethnicity. In contrast, our study
population was restricted to very obese patients; primarily white adolescent females who
were seeking obesity treatment. Thus, the results may not be comparable to this previous
study. Furthermore, the results of our study are not generalizable to less obese individuals or
to adolescents with diagnosed depression. Nevertheless, very obese adolescents have the
highest risk of developing diabetes during childhood and addressing potentially modifiable
risk factors is therefore relevant.
The prevalence of depressed mood is reported to be higher among males with type 2
diabetes than those with type 1 diabetes in the SEARCH for Diabetes in Youth study (30).
Currently, the directionality of the association between depressed mood and type 2 diabetes
in this pediatric cohort of patients is unknown. A prospective pediatric study evaluated
depressive symptoms, along with fasting measures of insulin sensitivity, in children aged 5–
13 years at a baseline visit, and again at a mean follow-up of 6 years (8). Depressive
symptoms at baseline were a significant predictor of fasting insulin and HOMA levels at
follow-up after controlling for BMI and other confounders; however, insulin secretion
measures were not obtained to determine β-cell function relative to insulin sensitivity. A few
additional pediatric studies have also found associations of indices of depression with
fasting measures of insulin sensitivity (9, 31). Our study design which included only very
obese insulin resistant adolescents (BMI ≥ 95th percentile; mean BMI 38.0 ± 7.7 kg/m2) who
were presenting to a tertiary care obesity center for treatment, may have precluded us from
finding a relationship between depressive symptoms and insulin sensitivity. We postulate
that the degree of obesity may have overshadowed any effect of depression on measures of
insulin sensitivity performed in this study. We did not adjust for the effect of puberty on
insulin sensitivity because all of the participants were at least Tanner stage III, and our
previous research demonstrates that pubertal insulin resistance accounts for a fraction of that
which is imparted by severe obesity (32, 33).
Many of the girls in our study had signs of untreated PCOS, which is known to be associated
with greater prevalence of pre-diabetes and depression (17). Although the percentage of
females with PCOS in each CDI group (CDI < 13 or ≥ 13) was the same, there was a
significant association between the CDI and oDI in these girls which is of clinical interest
and should be evaluated further in future studies. An additional limitation of our study is the
lack of information on socioeconomic status and family environment, which will be
important to include in future investigations. Our results did indicate a potential race effect
on the relationship between the CDI score and the oDI which has not been reported in
pediatrics and indicates need for further study in a larger more diverse study sample.
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Previously proposed mechanistic pathways linking anxiety, emotional stress, and depressive
symptoms to adverse cardiometabolic risk factors include greater potential for poor quality
sleep (34), sedentary lifestyle (35, 36), activation or dysregulation of the hypothalamic-
pituitary-adrenal axis leading to chronically increased levels of catecholamines (37), and
systemic inflammation and oxidative stress (38). Advances in the understanding of the
pathophysiology of type 2 diabetes and depression support a role for chronic inflammation
and oxidative stress in each of these conditions and provide evidence that shared
inflammatory mechanisms may link these conditions biologically (39, 40). While our study
was not designed to evaluate the mechanisms of this relationship, it indicates the need for
further studies examining such factors.
In conclusion, in this cohort of obese adolescents, higher depressive symptoms was
associated with evidence of impaired β-cell function relative to insulin sensitivity and more
dysglycemia compared with their equally obese peers who did not validate depressive
symptoms. From a clinical perspective, the relationship between depressive symptoms and
glucose tolerance abnormalities in obese adolescents at risk for type 2 diabetes should be
considered while evaluating these youth. From a research perspective, these relationships
should be investigated further to determine the directionality of the association, i.e. if early
recognition and treatment of depressive symptoms improves metabolic risk for type 2
diabetes.
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Figure I.
The correlation between log-transformed CDI score and (A) fasting glucose, (B) OGTT 2-hr
glucose, (C) OGTT glucose AUC and (D) oral disposition index (oDI). Subjects with CDI
total score < 13 are represented by empty circles and CDI total score ≥ 13 are represented by
filled circles.
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Table I
Demographic, Anthropometric, and Metabolic Characteristics of Participants According to Depressive
Symptoms (CDI score ≥ 13 indicates higher depressive symptoms)
Variable CDI score < 13 (6 ± 3; range 0 – 12) n = 42
CDI total score ≥ 13 (22 ± 5; range 13 – 28) n
= 14 P
Age 14.9 ± 1.7 (range 12.1 – 18.1) 15.1 ± 1.4 (range 12.7 – 17.4) 0.66
Sex (n; %) 0.75
 Female 27 (64.3) 10 (71.4)
 Male 15 (35.7) 4 (28.6)
Race (n; %) 0.06
 Non-Hispanic Black or bi-racial 20 (47.6) 2 (14.3)
 Non-Hispanic White 22 (52.4) 12 (85.7)
BMI (kg/m2) 38.0 ± 7.2 (range 28.2 – 55.5) 38.1 ± 9.1 (range 27.8 – 61.6) 0.95
BMI Z-score 3.3 ± 1.5 (range 1.53 – 8.31) 3.2 ± 1.6 (range 1.55 – 7.68) 0.87
Waist circumference (cm) 109.4 ± 17.8 110.6 ± 19.2 0.83
HbA1C (%) 5.4 ± 0.4 5.5 ± 0.4 0.24
Fasting insulin (μU/mL) 32.2 ± 19.4 36.7 ± 16.1 0.16
Fasting glucose (mg/dL) 88 ± 7 93 ± 6 0.028
OGTT 2-hr glucose (mg/dL) 122 ± 15 139 ± 23 0.020
Impaired fasting glucose 4.8% 14.3% 0.26
Impaired glucose tolerance 14.6% 42.9% 0.055
IFG or IGT 19.0% 50.0% 0.037
Diagnosed PCOS (females) 59.3% 60.0% 1.0
IGI30 4.49 ± 2.92 2.73 ± 1.57 0.024
oDI 15.2 ± 8.6 7.8 ± 3.7 0.001
OGTT Insulin AUC 22,090 ± 14,680 22,597 ± 10,429 0.91
OGTT Glucose AUC 14,963 ± 1,564 16,835 ± 1,919 0.001
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